About Our Current Research Studies
Our current studies and a brief description of each are listed below. More information about these studies, including eligibility criteria, funding sources, and team members involved can be found by clicking the study’s name.
A Two-Part Study of CLE-100 as an Adjunct Therapy in Subjects with Major Depressive Disorder
This study is to assess how well the CLE-100 improves depressive symptoms associated with MDD compared to placebo.
An Open-Lable Long-Term Extension Safety Study Of Esketamine Nasal Spray in Treatment-Resistant Depression
The main purpose of this study is to assess the long-term safety and tolerability, of esketamine nasal spray. Esketamine nasal spray has been approved by the United States Food and Drug Administration (FDA) for use in combination with an oral antidepressant, for the treatment of treatment-resistant depression (TRD) in adults. It is sold as SPRAVATO. It is still being studied to see if it is a safe and effective treatment for depression.
A Phase 3, Multicenter, Randomized, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
The purpose of this research is to test the effect of the investigational study drug compared to placebo on depression symptoms in patients who are taking an antidepressant that hasn’t fully helped their depression and to evaluate the safety of the investigational study drug and how well it is tolerated. The name of the study drug is pimavanserin.
A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
This study is a follow up study for ACP-103-059 (pimavanserin versus placebo).The purpose of this study is to assess the safety and tolerability of the long-term use of the study drug (pimavanserin) on symptoms of depression in patients who are taking an antidepressant that hasn’t fully helped their depression.
NMDA Receptor in Psychosis: Specific Auto-Antibodies
The goal is to find out more about psychosis and identify treatable mechanisms. Patients with serious psychoses will be tested for IgG antibodies directed against the NMDA receptor by collecting cerebrospinal fluid (CSF) and serum. CSF and sera will be collected in a total number of 50 patients with schizophrenia-spectrum psychosis and in 20 healthy controls.
Mechanism, Prediction and Treatment of Short -Term Risk for Suicidal Behavior
The purpose of the research is to find out patterns of behavior or emotions that may predict risk for suicide, and their response to lithium, a medicine that may reduce suicidal behavior.
Leveraging ethical dissension among capacity, beneficence and justice in clinical trials of neurotherapeutics in the severely disabled: lessons from schizophrenia
This study is to learn about participation in a clinical trial of a new neurosurgery treatment for individuals with schizophrenia or schizoaffective disorder. The goal is to see if patients with schizophrenia, schizoaffective disorder, and Parkinson’s disease meet the requirements and would be willing to try a new deep brain stimulation treatment if it was to become available.
MIND2- Dimensional Clinical, Neurophysiological, Molecular, and Genetic Phenotyping of Idiopathic Mental Illness
The purpose of this study is to combine several types of tests to understand how clinical problems such as having depression, anxiety or impulsivity develop. This study uses different approaches to understand mental symptoms in many different mood disorders. Clinical assessments, gait and balance testing, brain scans, pulse rate measurement, and blood samples will be collected in order to understand how mood disorders develop. Our goal is to learn how some behaviors and symptoms may overlap across multiple mood disorders.
A Phase 3, Multicenter, Long-term, Extension Study of the Safety and Efficacy of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type
The purpose of this research study is to look at how safe and how well AVP-786 works in Alzheimer’s patients with agitation over 12 months.
A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder who are early in their Illness
This research study looks at the effects of ALKS 3831(combination of olanzapine and Samidorphan) compared to olanzapine, on body weight in young adults with schizophrenia, schizophreniform, or bipolar I disorder who are early in their illness.